PMID- 31593087
OWN - NLM
STAT- MEDLINE
DCOM- 20191017
LR  - 20221005
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 98
IP  - 41
DP  - 2019 Oct
TI  - Combination of COX-2 inhibitor and metformin attenuates rate of admission in 
      patients with rheumatoid arthritis and diabetes in Taiwan.
PG  - e17371
LID - 10.1097/MD.0000000000017371 [doi]
LID - e17371
AB  - Rheumatoid arthritis (RA) is a chronic, systemic, inflammatory autoimmune disease 
      associated with increased prevalence of type 2 diabetes mellitus (T2DM). Here, we 
      investigated the effect of the combination of cyclooxygenase (COX)-2 inhibitors 
      and metformin on the rate of admission in patients with RA and T2DM and compared 
      it with that of only COX-2 inhibitors.In total, 1268 subjects with RA and T2DM 
      under COX-2 inhibitor and metformin therapy were selected from the National 
      Health Insurance Research Database of Taiwan, along with 2536 patients as 1:2 
      sex-, age-, and index year-matched controls without metformin therapy. Cox 
      proportional hazard analysis was used to compare the rate of admission during the 
      10 years of follow-up.At the end of the follow-up, 72 enrolled subjects (1.89%) 
      had admission, including 9 from the combination group (0.71%) and 63 from the 
      COX-2 inhibitor group (2.48%). The combination group was associated with a lower 
      rate of admission at the end of follow-up (P < .001). Cox proportional hazard 
      regression analysis revealed the lower rate of admission for subjects under 
      combination therapy (adjusted hazard ratio of 0.275; 95% confidence interval = 
      0.136-0.557, P < .001).Patients with RA and T2DM receiving the combination of 
      COX-2 inhibitors and metformin were associated with lower admission rate than 
      those on COX-2 inhibitors alone, and this effect may be attributed to the 
      decrease in the levels of proinflammatory factors.
FAU - Lu, Chieh-Hua
AU  - Lu CH
AD  - Department of Internal Medicine, Division of Endocrinology and Metabolism, 
      Tri-Service General Hospital, School of Medicine.
AD  - Department of Medical Research, Tri-Service General Hospital.
FAU - Chung, Chi-Hsiang
AU  - Chung CH
AD  - School of Public Health, National Defense Medical Center.
AD  - Taiwanese Injury Prevention and Safety Promotion Association.
FAU - Lee, Chien-Hsing
AU  - Lee CH
AD  - Department of Internal Medicine, Division of Endocrinology and Metabolism, 
      Tri-Service General Hospital, School of Medicine.
FAU - Su, Sheng-Chiang
AU  - Su SC
AD  - Department of Internal Medicine, Division of Endocrinology and Metabolism, 
      Tri-Service General Hospital, School of Medicine.
FAU - Liu, Jhih-Syuan
AU  - Liu JS
AD  - Department of Internal Medicine, Division of Endocrinology and Metabolism, 
      Tri-Service General Hospital, School of Medicine.
FAU - Lin, Fu-Huang
AU  - Lin FH
AD  - School of Public Health, National Defense Medical Center.
FAU - Tsao, Chang-Huei
AU  - Tsao CH
AD  - Department of Medical Research, Tri-Service General Hospital.
AD  - Department of Microbiology & Immunology.
FAU - Hsieh, Po-Shiuan
AU  - Hsieh PS
AD  - Department of Medical Research, Tri-Service General Hospital.
AD  - Department of Physiology and Biophysics.
AD  - Institute of Preventive Medicine, National Defense Medical Center, Taipei, 
      Taiwan, ROC.
FAU - Hung, Yi-Jen
AU  - Hung YJ
AD  - Department of Internal Medicine, Division of Endocrinology and Metabolism, 
      Tri-Service General Hospital, School of Medicine.
FAU - Hsieh, Chang-Hsun
AU  - Hsieh CH
AD  - Department of Internal Medicine, Division of Endocrinology and Metabolism, 
      Tri-Service General Hospital, School of Medicine.
FAU - Chien, Wu-Chien
AU  - Chien WC
AD  - Department of Medical Research, Tri-Service General Hospital.
AD  - School of Public Health, National Defense Medical Center.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Cyclooxygenase 2 Inhibitors)
RN  - 0 (Hypoglycemic Agents)
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - Aged
MH  - Arthritis, Rheumatoid/complications/*drug therapy
MH  - Cyclooxygenase 2 Inhibitors/*administration & dosage
MH  - Databases, Factual
MH  - Diabetes Mellitus, Type 2/complications/*drug therapy
MH  - Drug Therapy, Combination
MH  - Female
MH  - Hospitalization/*statistics & numerical data
MH  - Humans
MH  - Hypoglycemic Agents/*administration & dosage
MH  - Longitudinal Studies
MH  - Male
MH  - Metformin/*administration & dosage
MH  - Middle Aged
MH  - Proportional Hazards Models
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Taiwan/epidemiology
PMC - PMC6799465
COIS- The authors report no conflicts of interest.
EDAT- 2019/10/09 06:00
MHDA- 2019/10/18 06:00
PMCR- 2019/10/11
CRDT- 2019/10/09 06:00
PHST- 2019/10/09 06:00 [entrez]
PHST- 2019/10/09 06:00 [pubmed]
PHST- 2019/10/18 06:00 [medline]
PHST- 2019/10/11 00:00 [pmc-release]
AID - 00005792-201910110-00013 [pii]
AID - MD-D-19-02784 [pii]
AID - 10.1097/MD.0000000000017371 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2019 Oct;98(41):e17371. doi: 10.1097/MD.0000000000017371.